{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:04:32Z","timestamp":1785179072443,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021-46-2101-2023"],"award-info":[{"award-number":["Z-2021-46-2101-2023"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474134"],"award-info":[{"award-number":["82474134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104449"],"award-info":[{"award-number":["82104449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574643"],"award-info":[{"award-number":["82574643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109244","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:33:42Z","timestamp":1763627622000},"page":"109244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development"],"prefix":"10.1016","volume":"167","author":[{"given":"Long-tian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2025.109244_bb0005","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109244_bb0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-024-01674-1","article-title":"A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer","volume":"56","author":"Li","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bioorg.2025.109244_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s42003-024-07383-z","article-title":"Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer","volume":"8","author":"Zhang","year":"2025","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-024-01893-2","article-title":"Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts","volume":"9","author":"Kolesnichenko","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41698-024-00554-5","article-title":"ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework","volume":"8","author":"Timofeev","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109244_bb0030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","article-title":"Targeted therapy in cancer","volume":"76","author":"Tsimberidou","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109244_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: an overview of current understandings (review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.109244_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117414","article-title":"Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models","volume":"91","author":"Zhu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109244_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101077","article-title":"A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer","volume":"74","author":"Wang","year":"2024","journal-title":"Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104279","article-title":"Salt-inducible kinases (SIKs) in cancer: mechanisms of action and therapeutic prospects","volume":"30","author":"Manoharan","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109244_bb0055","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109244_bb0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109244_bb0065","article-title":"Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: a counterbalance between anti-tumor and pro-tumor","volume":"163","author":"Yi","year":"2023","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109244_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146471","article-title":"SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers","volume":"132","author":"Lu","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.109244_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13176","article-title":"SIKs control osteocyte responses to parathyroid hormone","volume":"7","author":"Wein","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109244_bb0080","doi-asserted-by":"crossref","unstructured":"Thuya, W. L., Cao, Y., Ho, P. C., Wong, A. L., Wang, L., Zhou, J., Nicot, C., & Goh, B. C. (2025). Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy. Cytokine Growth Factor Rev., S1359-6101(25)00003\u20136. Advance online publication. Doi: https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.003.","DOI":"10.1016\/j.cytogfr.2025.01.003"},{"key":"10.1016\/j.bioorg.2025.109244_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109244_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3892\/or.2024.8828","article-title":"Role of SIK1 in tumors: emerging players and therapeutic potentials (review)","volume":"52","author":"Zhang","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.109244_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115347","article-title":"Shifting the selectivity of pyrido[2,3-d] pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily","volume":"254","author":"Rak","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2025.109244_bb0100","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3390\/cancers16203441","article-title":"Targeting PARP-1 and DNA damage response defects in colorectal Cancer chemotherapy with established and novel PARP inhibitors","volume":"16","author":"Demuth","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109244_bb0105","doi-asserted-by":"crossref","unstructured":"Kim, DS., Camacho, C.V. & Kraus, W.L. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp. Mol. Med. 53, 42\u201351 (2021). Doi: https:\/\/doi.org\/10.1038\/s12276-021-00557-3.","DOI":"10.1038\/s12276-021-00557-3"},{"key":"10.1016\/j.bioorg.2025.109244_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108188","article-title":"Role of PARP-1 structural and functional features in PARP-1 inhibitors development","volume":"156","author":"Merkuryev","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109244_bb0115","first-page":"3537","article-title":"SIKs suppress tumor function and regulate drug resistance in breast cancer","volume":"11","author":"Xin","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109244_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2019.10.029","article-title":"SIK2 promotes reprogramming of glucose metabolism through PI3K\/AKT\/HIF-1\u03b1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer","volume":"469","author":"Gao","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.109244_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107059","article-title":"Glucose induced-AKT\/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia","volume":"128","author":"Chen","year":"2023","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ccell.2016.06.020","article-title":"Salt-inducible kinase 2 couples ovarian Cancer cell metabolism with survival at the adipocyte-rich metastatic niche","volume":"30","author":"Miranda","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41419-019-2221-x","article-title":"SIK2 enhances synthesis of fatty acid and cholesterol in ovarian cancer cells and tumor growth through PI3K\/Akt signaling pathway","volume":"11","author":"Zhao","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.109244_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41392-020-00265-w","article-title":"The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis","volume":"5","author":"Sun","year":"2020","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109244_bb0145","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.32604\/or.2025.062539","article-title":"SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers","volume":"33","author":"Li","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bioorg.2025.109244_bb0150","doi-asserted-by":"crossref","unstructured":"Zong, S., Dai, W., Fang, W., Guo, X., & Wang, K. (2020). SIK2 Promotes Cisplatin Resistance Induced by Aerobic Glycolysis in Breast Cancer Cells through PI3K\/AKT\/mTOR Signaling Pathway. Bioscience reports, BSR20201302. Advance online publication. Doi: https:\/\/doi.org\/10.1042\/BSR20201302.","DOI":"10.1042\/BSR20201302"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109244_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1042\/BCJ20160646","article-title":"Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages","volume":"474","author":"Darling","year":"2017","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109244_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.366","article-title":"Deficiency of salt-inducible kinase 2 (SIK2) promotes immune injury by inhibiting the maturation of lymphocytes","volume":"4","author":"Zhu","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2025.109244_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.109244_bb0170","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1038\/s41467-024-50912-x","article-title":"PARP1-dependent DNA-protein crosslink repair","volume":"15","author":"F\u00e1bi\u00e1n","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109244_bb0175","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41467-022-34148-1","article-title":"Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level","volume":"13","author":"Sefer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109244_bb0180","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109244_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2800488","article-title":"The PARP1 inhibitor niraparib represses DNA damage repair and synergizes with temozolomide for antimyeloma effects","volume":"2022","author":"Shen","year":"2022","journal-title":"J. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109244_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bioorg.2025.109244_bb0195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA repair: additional functions of PARP-1 in Cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0200","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","article-title":"PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation","volume":"9","author":"Ronson","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","article-title":"NAD (+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus","volume":"22","author":"Cant\u00f3","year":"2015","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109244_bb0210","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3892\/mmr.2021.12460","article-title":"Role of salt-inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells","volume":"24","author":"Ni","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.109244_bb0215","doi-asserted-by":"crossref","unstructured":"Ahmed, A. A., Lu, Z., Jennings, N. B., Etemadmoghadam, D., Capalbo, L., Jacamo, R. O., Barbosa-Morais, N., Le, X. F., Australian Ovarian Cancer Study Group, Vivas-Mejia, P., Lopez-Berestein, G., Grandjean, G., Bartholomeusz, G., Liao, W., Andreeff, M., Bowtell, D., Glover, D. M., Sood, A. K., & Bast, R. C., Jr (2010). SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell, 18(2), 109\u2013121. Doi: https:\/\/doi.org\/10.1016\/j.ccr.2010.06.018.","DOI":"10.1016\/j.ccr.2010.06.018"},{"issue":"8","key":"10.1016\/j.bioorg.2025.109244_bb0220","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-16-1562","article-title":"A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian Cancer cell lines and xenografts to paclitaxel","volume":"23","author":"Zhou","year":"2017","journal-title":"Clinical cancer research\u202f: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.bioorg.2025.109244_bb0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fonc.2020.00670","article-title":"Replication fork Remodeling and therapy escape in DNA damage response-deficient cancers","volume":"10","author":"Liptay","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109244_bb0230","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.tem.2018.09.007","article-title":"The salt-inducible kinases: emerging metabolic regulators","volume":"29","author":"Sakamoto","year":"2018","journal-title":"Trends in endocrinology and metabolism: TEM"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109244_bb0235","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/febs.14351","article-title":"14-3-3 proteins mediate inhibitory effects of cAMP on salt-inducible kinases (SIKs)","volume":"285","author":"Sonntag","year":"2018","journal-title":"FEBS J."},{"issue":"7160","key":"10.1016\/j.bioorg.2025.109244_bb0240","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature06128","article-title":"Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2","volume":"449","author":"Dentin","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109244_bb0245","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14728222.2016.1101452","article-title":"The diverse oncogenic and tumor suppressor roles of salt-inducible kinase (SIK) in cancer","volume":"20","author":"Du","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"issue":"33","key":"10.1016\/j.bioorg.2025.109244_bb0250","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1073\/pnas.0605579103","article-title":"Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon","volume":"103","author":"Overholtzer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109244_bb0255","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1128\/MCB.00380-16","article-title":"SIK2 restricts autophagic flux to support triple-negative breast Cancer survival","volume":"36","author":"Maxfield","year":"2016","journal-title":"Mol. Cell. Biol."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109244_bb0260","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41388-022-02259-0","article-title":"SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt\/\u03b2-catenin signaling","volume":"41","author":"Rong","year":"2022","journal-title":"Oncogene"},{"issue":"7\u20138","key":"10.1016\/j.bioorg.2025.109244_bb0265","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1515\/BC.1999.118","article-title":"A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation","volume":"380","author":"Hassa","year":"1999","journal-title":"Biol. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109244_bb0270","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1161\/STROKEAHA.117.017681","article-title":"Bosutinib attenuates inflammation via inhibiting salt-inducible kinases in experimental model of intracerebral Hemorrhage on mice","volume":"48","author":"Ma","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.bioorg.2025.109244_bb0275","doi-asserted-by":"crossref","unstructured":"Yong Kim, S., Jeong, S., Chah, K. H., Jung, E., Baek, K. H., Kim, S. T., Shim, J. H., Chun, E., & Lee, K. Y. (2013). Salt-inducible kinases 1 and 3 negatively regulate toll-like receptor 4-mediated signal. Molecular endocrinology (Baltimore, Md.), 27(11), 1958\u20131968. Doi: https:\/\/doi.org\/10.1210\/me.2013-1240.","DOI":"10.1210\/me.2013-1240"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109244_bb0280","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.18632\/oncotarget.2868","article-title":"NF-\u03baB signaling mediates acquired resistance after PARP inhibition","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109244_bb0285","doi-asserted-by":"crossref","unstructured":"Kim M. Y. (2011). Regulation of chromatin structure by PARP-1. Methods in molecular biology (Clifton, N.J.), 780, 227\u2013236. Doi: https:\/\/doi.org\/10.1007\/978-1-61779-270-0_14.","DOI":"10.1007\/978-1-61779-270-0_14"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109244_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146471","article-title":"SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers","volume":"132","author":"Lu","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109244_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115598","article-title":"Design, synthesis and development of a dual inhibitor of topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells","volume":"258","author":"Guha Majumdar","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab003","article-title":"Top1-PARP1 association and beyond: from DNA topology to break repair","volume":"3","author":"Chowdhuri","year":"2021","journal-title":"NAR cancer"},{"key":"10.1016\/j.bioorg.2025.109244_bb0310","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.csbj.2022.05.039","article-title":"Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib","volume":"20","author":"Shi","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109244_bb0315","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1021\/acsomega.1c00947","article-title":"Dasatinib-SIK2 binding elucidated by homology Modeling, molecular docking, and dynamics simulations","volume":"6","author":"Shi","year":"2021","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.bioorg.2025.109244_bb0320","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acschembio.6b00217","article-title":"Development of chemical probes for investigation of salt-inducible kinase function in vivo","volume":"11","author":"Sundberg","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109244_bb0325","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1021\/acs.jmedchem.0c02144","article-title":"Structure-based Design of Selective Salt-Inducible Kinase Inhibitors","volume":"64","author":"Tesch","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109244_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115469","article-title":"Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment","volume":"256","author":"Cai","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109244_bb0335","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tem.2018.08.004","article-title":"Salt-inducible kinases: physiology, regulation by cAMP, and therapeutic potential","volume":"29","author":"Wein","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109244_bb0340","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.celrep.2017.05.042","article-title":"A UV-independent topical small-molecule approach for melanin production in human skin","volume":"19","author":"Mujahid","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109244_bb0345","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acs.jmedchem.3c01428","article-title":"Optimization of selectivity and pharmacokinetic properties of salt-inducible kinase inhibitors that led to the discovery of Pan-SIK inhibitor GLPG3312","volume":"67","author":"Temal-Laib","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109244_bb0350","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1021\/acs.jmedchem.3c02246","article-title":"Discovery of clinical candidate GLPG3970: a potent and selective dual SIK2\/SIK3 inhibitor for the treatment of autoimmune and inflammatory diseases","volume":"67","author":"Peixoto","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109244_bb0355","unstructured":"National Center for Biotechnology Information (2025). PubChem Patent Summary for US-9260426-B2. Retrieved March 27, 2025 from https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9260426-B2."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109244_bb0360","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"10.1016\/j.bioorg.2025.109244_bb0365","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11523-019-00629-5","article-title":"Rucaparib: a review in ovarian Cancer","volume":"14","author":"Shirley","year":"2019","journal-title":"Target. Oncol."},{"issue":"18","key":"10.1016\/j.bioorg.2025.109244_bb0375","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0380","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/jm801171j","article-title":"Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer","volume":"52","author":"Penning","year":"2009","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109244_bb0385","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of Tumors with defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109244_bb0390","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/ph14080804","article-title":"Association between Olaparib exposure and early toxicity in BRCA-mutated ovarian Cancer patients: results from a retrospective Multicenter study","volume":"14","author":"Velev","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"17","key":"10.1016\/j.bioorg.2025.109244_bb0395","first-page":"1898","article-title":"Long-term survival in BRCA1 mutant advanced ovarian Cancer: unveiling the impact of Olaparib","volume":"14","author":"Afr\u0103s\u00e2nie","year":"2024","journal-title":"Diagnostics (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109244_bb0400","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/bjc.2016.41","article-title":"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","volume":"114","author":"Drew","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109244_bb0410","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.1016\/j.bmc.2008.05.044","article-title":"Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer","volume":"16","author":"Penning","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109244_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116405","article-title":"High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders","volume":"271","author":"Peng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109244_bb0420","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/nar\/gkh215","article-title":"Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2","volume":"32","author":"Oliver","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109244_bb0425","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs","volume":"64","author":"Johannes","year":"2021","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109244_bb0430","doi-asserted-by":"crossref","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): a CNS-penetrant, PARP1-selective inhibitor","volume":"67","author":"Johannes","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109244_bb0435","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.109244_bb0440","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast Cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:27:45Z","timestamp":1766107665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":88,"alternative-id":["S0045206825011241"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109244","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109244"}}